TrialInvestigational new drugs2011

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.

Jaafar Bennouna et al.PubMed ↗Publisher ↗

No numbers read from the abstract.